Skip to main content
SpringerLink
Log in

Tamoxifen and Cataracts: A Null Association

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Background. Previous studies have reported an increased risk of cataract for breast cancer patients treated with tamoxifen. We assessed whether breast cancer patients treated with tamoxifen were at increased risk of developing cataracts compared to women not prescribed tamoxifen.

Methods. We used a nested, matched case–control study design and data collected in the General Practice Research Database. We identified all women 30–79 years old who were diagnosed with breast cancer and treated with tamoxifen within 6 months, or with bladder cancer, colorectal cancer or non-melanoma skin cancer between January 1991 and December 1999. From this population, we identified all newly diagnosed cases of cataract. We matched four female controls to each case on age (± 1 year), index date and study entry date (± 6 months). We assessed the risk of cataracts for current, past and ever users of tamoxifen and according to cumulative use of tamoxifen. We calculated acataract risk factors. e was no evidence of an increased risk with increasing cumulative dose.

Findings. Current tamoxifen users were at no increased risk of cataract (AOR = 1.0, 95% CI: 0.7, 1.4). There was no evidence of an increased risk with increasing cumulative dose.

Interpretation. We detected no increased risk of cataract among breast cancer patients who were treated with tamoxifen compared to women with other cancers who were not prescribed tamoxifen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kaiser-Kupfer MI, Lippman ME:Tamoxifen retinopathy. Cancer Treat Rep 62:315–20, 1978

    Google Scholar 

  2. Beck M, Mills PV:Ocular assessment of patients treated with tamoxifen.Cancer Treat Rep 63:1833–1834, 1979

    Google Scholar 

  3. Vinding T, Nielsen NV:Retinopathy caused by treatment with tamoxifen in low dosage.Acta Ophthamol 61:45–50, 1983

    Google Scholar 

  4. Griffiths MFP:Tamoxifen retinopathy at low dosage.Am J Ophthamol 15:185–186,1987

    Google Scholar 

  5. Ashford AR, Donev I, Tiwari RP, Garrett TJ:Reversible ocular toxicity related to tamoxifen therapy.Cancer 61:33–35,1988

    Google Scholar 

  6. Gerner EW:Ocular toxicity of Tamoxifen.Ann Ophthamol 21:420–423, 1989

    Google Scholar 

  7. Bentley CR, Davies G, Aclimandos WA:Tamoxifen retinopathy:a rare but serious complication.Br Med J 304:495–496, 1992

    Google Scholar 

  8. Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G:Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. Cancer 69:2961–2964, 1992

    Google Scholar 

  9. Chang T, Gonder JR, Ventresca MR:Low-dose tamoxifen retinopathy.Can J Ophthamol 27:148–149, 1992

    Google Scholar 

  10. Nayfi eld SG, Gorin MB:Tamoxifen-associated eye disease: a review.J Clin Oncol 14:1018–1026, 1996

    Google Scholar 

  11. Zhang JJ, Jacob TJC:ATP-activated chloride channels inhibited by an antibody to P-glycoprotein.Am J Physiol 267:C1095–C1102, 1994

    Google Scholar 

  12. Zhang JJ, Jacob TJ, Valverde MA, Hardy SP, Mintenig GM, Sepulveda FV, Gill DR, Hyde SC, Trezise AE, Higgins CF:Tamoxifen blocks chloride channels:a possible mechanism for cataract formation.J Clin Invest 94:1690–1697, 1994

    Google Scholar 

  13. Zhang JJ, Jacob TJC, Hardy SP, Higgins CF, Valverde MA:Lens opaci fication by antioestrogens:tamoxifen vs ICI 182,780.Br J Pharmacol 115:1347–1348, 1995

    Google Scholar 

  14. Zhang JJ, Jacob TJC:Volume regulation in the bovine lens and cataract:the involvement of chloride channels.J Clin Invest 97:971–978, 1996

    Google Scholar 

  15. Furr BJA, Jordan VC:The pharmacology and clinical uses of tamoxifen.Pharmacol Ther 25:127–205, 1984

    Google Scholar 

  16. Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, Gomolin JE, Margolese RG, Mathen MK, Bowman DM, Kaufman DI, Dimitrov NV, Singerman LJ, Bornstein R, Wolmark N:Long-term tamoxifen citrate use and potential ocular toxicity.Am J Ophthalmol 125: 493–501, 1998

    Google Scholar 

  17. Fisher B, Costantino JP, Wickerham L, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N:Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study.J Natl Cancer Inst 90:1371–1388, 1998

    Google Scholar 

  18. Paganini-Hill A, Clark LJ:Eye problems in breast cancer patients treated with tamoxifen.Breast Cancer Res Treat 60:167–172, 2000

    Google Scholar 

  19. Early Breast Cancer trialists' Collaborative Group:Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy:133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women.Lancet 339:1–15, 1992

    Google Scholar 

  20. The Scottish Trial.Report from the Breast Cancer Trials Committee,Scottish Cancer Trials Office (MRC),Edinburgh:adjuvant tamoxifen in the management of operable breast cancer:Lancet 2:171–75, 1987

    Google Scholar 

  21. Nolvadex Adjuvant Trial Organisation:controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer:analysis at six years.Lancet 1:836–840, 1985

    Google Scholar 

  22. Rutqvist LE, Cedermark B, Glas U, Johansson H, Nordenskjold B, Skoog L, Somell A, Theve T, Friberg S, Askergren J:The Stockholm trial on adjuvant tamoxifen in early breast cancer.Correlation between estrogen receptor level and treatment effect.Breast Cancer Res Treat 10:255–266, 1987

    Google Scholar 

  23. Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, Plotkin D, Wolter J, Bornstein R, LegaultPoisson S et al.:Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer:5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.J Clin Oncol 4:459–471, 1986

    Google Scholar 

  24. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER et al.:A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 320:479–484, 1989

    Google Scholar 

  25. Garcia Rodriguez LA, Perez Gutthann SP:Use of the UK general practice research database for pharmacoepidemiology.Br J Clin Pharmacol 45:419–425, 1998

    Google Scholar 

  26. Jick H, Jick SS, Derby LE.Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.Br Med J 302:766–768, 1991

    Google Scholar 

  27. Jick H, Terris BZ, Derby LE, Jick SS:Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Safety 1:347–349, 1992

    Google Scholar 

  28. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H:Validity of the general practice research database. Pharmacotherapy 23:686–689, 2003

    Google Scholar 

  29. Derby L, Maier WC.Risk of cataracts among users of intranasal corticosteroids.J Allergy Clin Immunol 105: 912–916,2000

    Google Scholar 

  30. Longstaff S, Sigurdsson H, O'Keefe M, Ogston S, Preece P: A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer Clin Oncol 25:1805–1808,1989

    Google Scholar 

  31. Fisher B, Dignam J, Bryant J, Wolmark N:Five versus more than five years of tamoxifen for lymph node-negative breast cancer:updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.J Natl Cancer Inst 93:684–690,2001

    Google Scholar 

  32. Kaye JA, Derby LE, del Mar Melero-Montes M, Quinn M, Jick H:The incidence of breast cancer in the General Practice Research Database compared with national cancer registration data.Br J Cancer 83:1556–1568,2000

    Google Scholar 

  33. Earle CC, Burstein HJ, Winer EP, Weeks JC:Quality of non-breast cancer health maintenance among elderly breast cancer survivors.J Clin Oncol 21:1447–1451,2003

    Google Scholar 

  34. Kattlove H, Winn RJ:Ongoing care of patients after primary treatment for their cancer.CA Cancer J Clin 54: 172–196,2003

    Google Scholar 

  35. Fraunfelder FT, Meyer SM:Ocular toxicity of antineoplastic agents.Ophthalmology 90:1–3,1983

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology, Boston University School of Public Health, Boston

    Brian D. Bradbury, Timothy L. Lash, James A. Kaye & Susan S. Jick

  2. Boston Collaborative Drug Surveillance Program, 11 Muzzey Street, Lexington, MA, 02421, USA; Tel.:

    Brian D. Bradbury

  3. Geriatrics Section, Department of Medicine, Boston University School of Medicine, Boston, MA, USA

    Timothy L. Lash

  4. Boston Collaborative Drug Surveillance Program, Lexington, MA, U S A

    James A. Kaye & Susan S. Jick

Authors
  1. Brian D. Bradbury
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy L. Lash
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James A. Kaye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Susan S. Jick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bradbury, B.D., Lash, T.L., Kaye, J.A. et al. Tamoxifen and Cataracts: A Null Association. Breast Cancer Res Treat 87, 189–196 (2004). https://doi.org/10.1023/B:BREA.0000041626.76694.85

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:BREA.0000041626.76694.85

Search

Navigation